Coronavirus Infections Clinical Trial
Official title:
Seroprevalence of IgG Antibodies to Middle East Respiratory Syndrome Coronavirus in Asymptomatic Healthcare Workers After Treatment of Confirmed MERS Patient
The investigators aim to do serosurvey of healthcare-personnel who had participated in
treatment of confirmed patients of Middle-East respiratory syndrome. The investigators
collected the base-line (pre-exposure) serum of healthcare-personnel in a few centers, and
will collect the post-exposure serum from about 25-30 centers in which confirmed MERS
patients had been treated.
The investigators will deduct the seroprevalence of MERS-CoV IgG among the healthy
healthcare-personnel, and calculate the sero-conversion rate if possible. The investigators
will subdivided the seroprevalence according to the degree of exposure and preparedness of
personal protective equipment.
We aim to deduct the seroprevalence of healthcare-personnel (HCP) who had participated in
treatment of confirmed patients of Middle-East respiratory syndrome.
In first step, we collected the base-line (pre-exposure) serum from the HCP who worked in
the hospitals in which confirmed MERS patients were treated. Pre-exposure serum was
collected in a few centers. If the serum was drawn within 3 weeks from initial exposure,
then the serum was considered adequate as pre-exposure. (Because, antibody against the
MERS-CoV would be produced after more the 17-21 days of exposure). The serum was frozen.
In second step, we will collect the post-exposure serum from the HCP who worked in the
hospitals in which confirmed MERS patients were treated or detected. We plan to include
25-30 centers. The timing of sample collection is 6-8 weeks after last contact with
confirmed MERS patients. The serum will also freeze.
In third step, we will assay the presence of antibody in collected sample. We will use
MERS-CoV ELISA kit (EUROIMMUNE co.) as screening test and MERS-CoV IFA kit (EUROIMMUNE co.)
as confirm test.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04553575 -
CoViD-19 Patient in Reims University Hospital in March to April 2020
|
||
| Active, not recruiting |
NCT05033847 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 2 | |
| Active, not recruiting |
NCT05548439 -
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
|
Phase 1 | |
| Completed |
NCT05046548 -
This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05726084 -
Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05069129 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05054075 -
Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19
|
Phase 2 | |
| Recruiting |
NCT05599516 -
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial
|
Phase 3 | |
| Completed |
NCT05047900 -
The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community
|
N/A | |
| Completed |
NCT04420286 -
Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
|
||
| Completed |
NCT04424355 -
Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
|
||
| Completed |
NCT05083039 -
Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
|
||
| Terminated |
NCT04409873 -
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
|
Phase 2 | |
| Enrolling by invitation |
NCT04327349 -
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
|
N/A | |
| Completed |
NCT04321278 -
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)
|
Phase 3 | |
| Recruiting |
NCT04327570 -
In-depth Immunological Investigation of COVID-19.
|
||
| Completed |
NCT04326309 -
Audio Data Collection for Identification and Classification of Coughing
|
||
| Recruiting |
NCT04322344 -
Escin in Patients With Covid-19 Infection
|
Phase 2/Phase 3 | |
| Completed |
NCT04328129 -
Household Transmission Investigation Study for COVID-19 in Tropical Regions
|
N/A | |
| Completed |
NCT04323592 -
Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
|